Ekso Bionics Holdings, Inc. Common Stock Q2 FY2024 Earnings Call

· Earnings call transcript and AI-powered summary

Key Financial Highlights (Q2 2024 vs. Q2 2023)

  • Record quarterly revenue: $5.0 million (up from $4.7 million)
  • EksoHealth devices sold: 37 units
  • Gross profit: $2.6 million (53% margin, improved from $2.3 million / 48% margin) — driven by higher average selling price for EksoNR and lower device/service costs
  • Operating expenses: $5.0 million (down from $6.5 million) — due to lower headcount, discretionary payroll, consultant, and labor costs
  • Net loss: $2.4 million or $0.13 per basic/diluted share (improved from $4.2 million or $0.31 per share)

First Half 2024 vs. First Half 2023

  • Revenue: $8.7 million (down slightly from $8.8 million)
  • EksoHealth devices sold: 66 units
  • Gross profit: $4.6 million (53% margin, improved from $4.3 million / 48% margin)
  • Operating expenses: $10.2 million (down from $13.0 million) — absence of prior-year acquisition/integration costs plus lower discretionary expenses
  • Net loss: $5.8 million or $0.33 per share (improved from $8.6 million or $0.64 per share)
  • Cash and restricted cash (as of June 30, 2024): $5.9 million (down from $8.6 million at Dec 31, 2023)

Operational & Strategic Updates

Continue Reading

Unlock the full AI-powered summary with key highlights, financial performance, and analyst Q&A.

Upgrade to Professional
Operator: Greetings, and welcome to the Ekso Bionics' Q2 2024 Financial Results Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Matt Steinberg with Finn Partners. Thank you, Matt. You may begin. Matt Steinberg: Thank you, operator, and thank you all for participating in today's call. Joining me from Ekso Bionics are Scott Davis, Chief Executive Officer; and Jerome Wong, Chief Financial Officer. Earlier today, Ekso Bionics released financial results for the quarter ended June 30, 2024. A copy of the press release is available on the company's website. Before we begin, I would like to remind you that management will make statements during this call that include forward-looking statements within the meaning of the federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements made during this call that are not statements of historical facts should be deemed to be forward-looking statements. All forward-looking statements, including statements regarding our business strategy, future financial or operating expectations or our expectations of the regulatory landscape governing our products and operations are based upon management's current estimates and various assumptions. These statements

Continue Reading

Unlock the full earnings call transcript with speaker labels and formatted dialogue.

Upgrade to Professional